Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes

• DOI: 10.1111/apt.15102
• Publication Date: 2019-01-17T00:53:57Z
• Authors: Jia Li; Stuart C. Gordon; Loralee B. Rupp; Talan Zhang; Sheri Trudeau; Scott D. Holmberg; Anne C. Moorman; Philip R. Spradling; Eyasu H. Teshale; Joseph A. Boscarino; Mark A. Schmidt; Yihe G. Daida; Mei Lu
• Keywords: Hepatitis C; Stroke

Summary Background The role of hepatitis C ( HCV ) eradication on the long‐term complications type 2 diabetes mellitus remains incompletely studied. Aim To investigate whether antiviral treatment impacted risk acute coronary syndrome, end‐stage renal disease, ischaemic stroke, and retinopathy among diabetic patients from four US health systems comprising Chronic Hepatitis Cohort Study CH e CS ). Methods We included with diagnosis codes for who were antidiabetic medications. Patients followed until an outcome interest, death, or last system encounter. effect outcomes was estimated using competing analysis (Fine‐Gray subdistribution hazard ratio [ sHR ]), death as a event. Results Among 1395 ‐infected diabetes, 723 (52%) treated either interferon‐based direct‐acting antivirals DAA s); 539 (75% treated) achieved sustained virological response SVR After propensity score adjustment to address selection bias, demonstrated significantly decreased syndrome (sHR = 0.36; P < 0.001), disease 0.46; stroke 0.34; 0.24; 0.001) compared untreated patients. consistent in subgroup analyses ‐treated interferon‐treated patients, cirrhotic well sensitivity considering cause‐specific hazards, exclusion on‐treatment retinopathy, status time‐varying covariate. Conclusion Successful reduces incidence regardless cirrhosis. Our findings support importance therapy reduce these extrahepatic outcomes.